EU parliament backs deregulation of New Genome Techniques
With the MEPs' approval of the amendments to the European Commission's draft legislation, the way is now clear for a regulation that distinguishes...
Gut bacteria seed autoimmunity-inducers
A unique mechanism, reported by an Irish-French research team underscores an emerging theme in microbiome research: that disruptions to gut bacteria...
Amsilk partners with 21st.BIO
Advanced materials specialist AMSilk GmbH (Neuried, Germany) and biotech production specialst 21st.BIO (Copenhagen) have announced to join forces to...
Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
Pierre Fabre SAS in US$31m licence deal with Kinnate Biopharma Inc
With the US$31m agreement Pierre Fabre licences the global rights to exarafenib and other pan-RAF program assets from Kinnate...
Biovian and 3P Biopharmaceuticals join forces to create 3PBIOVIAN
Finnish Biovian Oy and Pamplona-based 3P Biopharmaceuticals Srl have joined forces to build a pan-European Contract Development and Manufacturing...
Jazz Pharmaceuticals licences KRAS blocker from Redx Pharma
Under the term of the agreement, Redx Pharma plc (Alderley Park, UK) is to receive US$10m upfront and up to US$870m in milestone payments. Redx is...